Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Flurpiridaz F-18

Drug Profile

Flurpiridaz F-18

Alternative Names: 18F-flurpiridaz; BMS-747158; BMS-747158-02

Latest Information Update: 02 Jul 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lantheus Medical Imaging
  • Class Imaging agents; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Coronary artery disease

Most Recent Events

  • 08 Jun 2018 GE Healthcare initiates a phase III trial in Coronary artery disease (Diagnosis) in USA (IV) (NCT03354273)
  • 06 Dec 2017 GE Healthcare plans a phase III trial in Coronary artery disease (Diagnosis) in USA (IV) (NCT03354273)
  • 25 Apr 2017 Flurpiridaz F 18 licensed to GE Healthcare in World
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top